abstract caught attent
get memori day weekend want share abstracts/sess found
interest plan explor rsvp kol
dinner saturday look forward discuss ran reshef tanguy seiwert
egfr target resist
abstract egfr-cmet bispecif antibodi egfr-driven advanc non-smal cell lung cancer nsclc
idea bispecif antibodi overcom cmet-driven resist egfr inhibit difficult space random trial
failur combin egfr cmet inhibitor versu egfr inhibit alon abstract respons evalu patient
rel esmo abstract orr roughli patient prior exposur third-gener egfr inhibitor
pr confirm identifi genet resist egfr inhibit patient could interest nich
patient fail sever prior egfr inhibitor
abstract safeti preliminari antitumor activ antibodi drug conjug egfr tki-resist egfrm
data metastat breast cancer san antonio breast cancer symposium compel orr
exampl know target success despit role oncogen signal resist
inhibitor signal blockad alon doesnt seem effect perhap necessari present
first clinic data lung cancer knowledg abstract show orr egfr mutant nsclc patient
neg diseas progress erlotinib gefitinib afatinib develop diseas progress osimertinib regardless
statu impress orr let see full data look like
head neck cancer
abstract protocol-specifi final analysi phase trial pembrolizumab pembro first-lin therapi recurrent/
metastat head neck squamou cell carcinoma r/m hnscc
analyst certif disclosur pleas see page
much say trial saw esmo demonstr pembrolizumab alon superior extrem regimen
chemotherapi recurrent/metastat head neck cancer patient high pembro chemo superior biomark unselect patient
compar extrem sever present session although mostli discuss chemotherapi optim
side t-cell therapi cytokin releas syndrom neurolog toxic financi burden
attend whole session particularli interest talk barrier car-t cell treatment commun figur
note point car-t sale indic referr rate commun set analysi done
period time gilead yescarta primarili sold us growth sale quick calcul
patient treat use net price therapi suggest patient per year get car-t consist
expert told us low referr rate commun center
phase studi blocker combin establish anti-cancer antibodi patient advanc malign
continu believ inhibit valid new anti-canc mechan base data non-hodgkin lymphoma poster
privat compani oncolog develop sirpa-fc fusion molecul fc inactiv minimize/avoid on-
target anemia look forward full data especi gastric cancer/gastroesophag junction cancer cohort abstract show
orr patient treat trastuzumab patient progress prior trastuzumab fluoropyrimidine-bas therapi
also check poster discuss session june
safeti efficaci adopt cell transfer use autolog tumor infiltr lymphocyt treatment recurr metastat
one caught us guard data til therapi melanoma slightli underwhelm view data cervic cancer
impress orr earli day studi evalu patient two respons unconfirm also
interest see baselin patient characterist understand healthiest patient typic candid til therapi
still orr much higher would expect checkpoint inhibitor therapi
potenti target de-coupl checkpoint inhibitor-induc coliti antitumor immun
tocilizumab use car-t therapi address cytokin releas syndrom manag immun relat advers event
abstract make us wonder could role broadli includ inhibit major on-target ae immune-
phase ii studi autolog tumor infiltr lymphocyt til patient solid tumor
studi interest sinc cohort patient treat til therapi cohort patient treat til therapi
wonder much overlap til therapi checkpoint inhibit infus til get block pd-
abl overcom immun suppress tumor microenviron studi might help answer question
random phase trial mitochondri inhibitor placebo ad antiangiogen aa bevacizumab earli
abstract outperform pt mitochondri inhibitor random studi treatment-nav
early-stag breast cancer patient receiv singl dose bevacizumab follow either day placebo
statist signific differ two group decreas treat patient versu increas
placebo treat patient asset larg part thesi random data look interest
phase i/ii multipl expans cohort trial patient advanc solid tumor kra mutat
poster goe design phase i/ii studi mirati kra inhibitor compani report efficaci data
program interest compar result discuss percept
moment mirati compound may better
phase studi neoantigen vaccin base autolog peptid immun respons
previous wrote abstract discuss first in-human immunogen result genocea lead neoantigen
vaccin candid data abstract show patient receiv vaccin immun respons detect total
administ neoantigen upheld entir cohort part studi would best-in-class neoantigen recognit rate across current
select platform disappoint immunogen data neon ntgn privat neoantigen program
wait see might ultim translat clinic efficaci remain intrigu genocea atla platform compani
also host confer call june et discuss data
first-in-human phase i/ii trial inhibitor subject advanc cancer
phase i/ii first-in-human trial oral inhibitor given combin low-dos gemcitabin subject advanc
target drug class flop date recent discontinu roche/genentech vtx rog vx eli
lilli nyse prexasertib develop differ program either test exclus patient genet
alter hypothes induc synthet lethal inhibit dose way enabl
full target coverag maintain toler safeti profil prexasertib present first efficaci data
present see compani found popul inhibit lead promis activ abstract
combo studi indic proof-of-concept clinic activ seen tumor type anal cervic rectal note sierra
also host confer call june ct discuss result detail
hematolog malignanciesleukemia myelodysplast syndrom allotranspl
abstract random phase ii trial standard therapi elderli patient acut myeloid leukemia aml
weve never heard privat compani florida call drug heparin deriv substanti
reduc anti-coagul activ appar impact axi alter leukem stem cell adhes studi design
newli diagnos elderli aml patient random receiv standard induct chemotherapi chemo low dose mg/kg/hr
chemo high dose mg/kg/hr abstract note baselin characterist similar across group data
evalu patient patient treat cr/cri patient high dose group low dose
chemotherapi statist signific improv event free surviv high dose versu chemo
trend toward surviv benefit interest random data note given continu infus still
cr/cri impress
development immunotherapi tumor immunobiolog
abstract first-in-human studi human monoclon antibodi mab cemiplimab patient pt
neg dataset asset respons evalu patient fact session dedic fail trial small
uninterpret dataset one dataset phase trial inhibitor monotherapi
combin antagonist candid target adenosin pathway thought immunosuppress
enrol patient monotherapi combo advanc cancer singl tumor regress observ prostat cancer patient
let see data look confer still convinc adenosin pathway next big thing io
contessa multi-national multicent random phase registr studi tesetaxel plu reduc dose capecitabin patient pt
hormon receptor hr local advanc metastat breast cancer la/mbc previous receiv taxan
recent initi coverag odon outperform pt poster describ on-going random phase trial
support first approv tesetaxel oral taxan initi detail think tesetaxel right profil oral
minim hair loss low rate neuropathi becom wide use breast cancer
first-in-human phase studi antibody-drug conjug advanc solid tumor dose-expans cohort patient pt
non-squam non-smal cell lung cancer nsq nsclc
flag poster notic rate kerat corneal inflammation/corn cloud studi high someth
watch evalu data antibody-drug conjug perhap later-lin nsclc patient much issu reduc
vision big deal patient
phase ii studi bemcentinib first-in-class highli select inhibitor pembrolizumab pt advanc nsclc os
stage preliminari stage ii efficaci
weve mean look bergenbio select inhibitor monotherapi data r/r aml cr/cri
look better evalu patient low level solubl dataset patient previously-
treat io-nav stage iv lung cancer evalu respons avail biopsi consid posit
differ blood-bas assay patient combin pembrolizumab led orr small
dataset someth well keep eye one thing interest see time patient consid posit
rememb mirati troubl find patient test glesatinib nsclc patient rearrang gene amplif
educ session keen hear high-level thought expert hr mbc follow initi coverag
one session chair sara tolaney lead odon recent announc contessa trio studi contessa
trio arm elderli metastat breast cancer patient treat single-ag tesetaxel oral taxan addit
arm patient tnbc random tesetaxel pembrolizumab tesetaxel nivolumab tesetaxel atezolizumab
assay checkpoint inhibitor also evalu patient awar studi sever checkpoint inhibitor
compar random fashion multipl assay evalu systemat data regard tesetaxel
inhibit interest sure type studi could draw much broader audienc that interest rel activ
checkpoint inhibitor assay
plenari session includ distinguish achiev award scienc oncolog award lectur
announc random placebo pbo -control double-blind phase ph trial doxorubicin dox olaratumab versu dox pbo
patient pt advanc soft tissu sarcoma st
top-line result trial announc januari puzzler sure olaratumab approv sinc octob
patient metastat soft tissu sarcoma st approv base posit random clinic trial show longer overal
surviv olaratumab doxorubicin versu doxorubicin monotherapi larger announc trial fail show improv os
broader st popul smaller leiomyosarcoma subgroup could understand failur confirmatori studi drug approv
basi single-arm trial orr primari endpoint os advantag prior random studi let see
present help us understand happen
development therapeut tumor biolog nonimmuno
sever interest present session includ data amgen kra inhibitor erk inhibitor
novel target bayer inhibitor
abstract phase studi evalu safeti toler pharmacokinet pk efficaci novel small molecul
inhibitor advanc solid tumor
im sure well cover other remain optimist long-term prospect kra inhibitor think take
time mani addit trial fulli optim respons durabl patient treat agent abstract confirm select
kra inhibitor produc clinic activ lung cancer patient give us real inform frequenc patient respond
abstract way low extrapol long answer question may come cours year
watch c-met inhibitor talk novartiss nyse nv capmatinib merck kgaa mrk gr tepotinib select c-met
inhibitor target lung cancer patient exon skip mutat like becom part practic also intrigu abstract data
takeda nyse tak inhibitor studi nsclc patient egfr exon insert main
focu efficacy/safeti profil given ae profil spectrum poziotinib also go exon insert
popul difficult toler mani patient
result inhibitor alon rituximab relapsed/refractori r/r follicular lymphoma fl
abstract outperform pt cover separ note highlight
activ remain strong highest orr seen inhibitor
respons rate high patient continu exposur intermitt schedul
delay immune-rel ira lower patient look like wait full updat
poster discuss session abstract also present result oral session
intern confer malign lymphoma icml june lugano switzerland poster focus
patient fl data icml includ patient fll cll sll
first-in-class antibodi activ well toler alon azacitidin aml md patient initi phase result
abstract forti seven outperform pt cover separ note highlight
look activ combin azacitidin cr/cri
quick time respons also suggest activ
respons monotherapi r/r diseas
favor tox profil could read combin
durabl yet reach mrd- statu half respond
poster discuss session abstract
identifi protein depend use dimerization-specif antibodi biomark predict respons target apoptosi induc therapi
take look poster sinc inhibitor remind involv transcript elong inhibit
lead deplet short-liv transcript one key transcript decreas follow inhibit famili member
act block cellular apoptosi think tolero data clinic valid resist mechan
aml poster discuss vitro method predict respons inhibitor keep mind oral
inhibitor clinic develop awar
efficaci time next treatment follow lenalidomide/rituximab rituximab/placebo patient r/r indol nhl augment
data poster show patient nhl treat rituximab lenalidomid greater respons rate subsequ
therapi compar patient treat rituximab median also longer subsequ therapi patient receiv captur
type metric way collect overal surviv data import consid well poorli patient particular
therapi mention next abstract lymphoma patient fail car-t poor prognosi make us wonder earli
treatment paradigm technolog like car-t could use
outcom larg b-cell lymphoma progress axicabtagen ciloleucel axi-cel result us lymphoma car-t consortium
abstract describ outcom r/r larg b-cell lymphoma patient trial approv studi gilead yescarta
check number
patient receiv salvag therapi diseas progress median salvag therapi rang
median os follow relaps day mo
patient relaps month yescarta receiv addit therapi median os day
patient relaps month yescarta receiv addit therapi median os day mo
patient relaps month yescarta receiv addit therapi median os day mo
hypothes patient fail car-t earli poor prognosi prognosi good gener r/r larg b-cell
lymphoma patient salvag therapi perhap time gap apheresi car-t infus increas difficulti treat
updat single-arm phase ii l-mind studi lenalidomid relapsed/refractori diffus larg b-cell lymphoma r-r
dlbcl respons rate patient subgroup poor prognosi
follow l-mind data better understand influenti morphosyss mab might dlbcl market
approv full data trial patient treat plu lenalidomid present lugano confer
june orr cr mdor doc weve spoken like data present prior recent updat
although wonder would sequenc car-t given target overlap data dlbcl regard
loss patient relaps studi center also europ none doc spoke treat patient
anoth quick comment data look abstract abstract report data patient dlbcl high-grad nhl
treat lenalidomid univers rochest orr cr rate rememb monotherapi r/
 dlbcl led orr cr rate interest combin lead cr rate could result
mani factor includ synergi lenalidomid healthier patient l-mind trial etc
hematolog malign lymphoma chronic lymphocyt leukemia
curiou hear idea expert topic like
evolv option follicular lymphoma
bad ugli
awaken immun system dlbcl
car-t
check whole session includ interest data two -t program address solid tumor claudin gastric
pancreat cancer mesothelin pleural cancer one dual-target -t program non-hodgkin lymphoma
abstract sophia primari analysi phase studi margetuximab chemotherapi versu trastuzumab patient pt
metastat met breast cancer mbc prior therapi tx
antibodi margetuximab engin greater bind activ allel minim bind
inhibitori fcr initi top-line data sophia studi show modest improv metastat breast cancer
patient receiv margetuximab chemo versu patient receiv trastuzumab chemo patient patient
allel updat result show month prolong os patient margetuximab arm
allel patient studi
abstract updat overal surviv os global random double-blind placebo-control phase studi
atezolizumab atezo nab-paclitaxel np previous untreat local advanc metastat triple-neg breast cancer mtnbc
studi serv basi approv abraxan tecentriq metastat tripl neg breast cancer patient interest
see full data sinc recent initi discuss contessa trio studi tnbc
abstract salvag therapi failur singl agent treatment studi german adoreg melanoma registri
weve mani convers investor patient fail checkpoint inhibitor therapi re-challeng
respons rate re-challeng high depend sever factor includ time prior checkpoint inhibitor exposur re-
rechalleng abstract present data real-world treatment patient advanc melanoma germani dataset includ
patient ipilimumab-nav unresect melanoma fail treatment single-ag start next system therapi
within month failur patient re-expos combin respons
patient treat ipilimumab regimen chemo achiev respons respect anoth data point consid
evalu single-arm trial data experiment agent test combin re-challeng set orr
trial better spectacular otherwis like observ activ mostli come alon
risk invest
investor consid risk invest stock high risk high volatil clinic stage biopharmaceut compani
asset may success clinic trial may fail gain regulatori approv product launch possibl revenu
meet investor expect product face unexpect competit revenu approv product may also meet investor
expect approv one diseas alway correl success approv anoth diseas overal market condit may also
affect valu underli secur
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
